placebo + NUC

This is a combination of a placebo and a "NUC." In clinical research, "placebo" refers to an inert substance with no therapeutic effect, used as a control in trials. "NUC" most commonly refers to nucleos(t)ide analogues—antiviral drugs that inhibit viral polymerase activity and are widely used in the treatment of chronic hepatitis B and other viral infections. NUCs suppress viral replication by inhibiting reverse transcriptase or DNA polymerase but do not eradicate covalently closed circular DNA (cccDNA), requiring long-term administration for effective disease management[6][8]. The specific identity of the NUC in this context is not provided; it could refer generically to any nucleos(t)ide analogue or potentially to a specific agent such as NUC-7738 (fosdesdenosine sipalabenamide), which is under investigation for cancer therapy[1]. This combination would be used in clinical trials where one arm receives both an active antiviral agent (a NUC) and another receives placebo plus the same agent, or possibly where two separate arms receive either placebo or a NUC.